Related Experiment Video
Updated: May 25, 2025
02:21
Microscopic Electric Rotary Grinding of Plaques Combined with Graft Repair in the Management of Peyronie's Disease
Published on: March 15, 2024
539
Targeting TRPC-5 Channel Inhibition to Improve Penile Vascular Function in Erectile Dysfunction.
Mariam El Assar1,2,3, Borja García-Gómez4, José M La Fuente5
1Fundación para la Investigación Biomédica del Hospital de Getafe, 28905 Getafe, Spain.
International Journal of Molecular Sciences
|February 26, 2025
Summary
Targeting TRPC5 channels with AC1903 improves penile vascular function in aging rats and erectile dysfunction (ED) patients. This TRPC5 inhibition enhances PDE5 inhibitor efficacy, offering a potential therapeutic strategy for ED.
Area of Science:
- Urology
- Vascular Biology
- Pharmacology
Background:
- Canonical transient receptor potential (TRPC) channels are crucial for calcium homeostasis, impacting penile vascular contractility and erectile dysfunction (ED).
- TRPC channel dysregulation is implicated in the pathophysiology of ED.
Purpose of the Study:
- To investigate the effect of TRPC5 inhibition on penile vascular endothelial function in aging rats and ED patients.
- To assess the impact of TRPC5 inhibition on the efficacy of phosphodiesterase type 5 (PDE5) inhibitors.
Main Methods:
- Evaluated TRPC inhibitor-induced relaxations in corpus cavernosum (RCC) from aged rats and human penile tissues (corpus cavernosum - HCC, penile resistance arteries - HPRAs) from ED patients and organ donors.
- Assessed the effect of the TRPC5 inhibitor AC1903, alongside TRPC3 and TRPC4 inhibitors, on vascular relaxations.
- Determined the potentiation of tadalafil (a PDE5 inhibitor) relaxation by AC1903 in human penile tissues.
Main Results:
- The TRPC5 inhibitor AC1903 demonstrated superior relaxation effects in aged RCC, HCC, and HPRAs from ED patients compared to TRPC3 and TRPC4 inhibitors.
- AC1903 enhanced endothelial and neurogenic relaxations in aged rat RCC and improved endothelium-dependent relaxation in human HCC and HPRAs from ED patients.
- AC1903 potentiated tadalafil-induced relaxations in human penile tissues from ED patients.
Conclusions:
- TRPC5 inhibition significantly improves penile vascular function in aged rats and ED patients.
- TRPC5 inhibition represents a promising therapeutic target for ED, potentially enhancing outcomes when combined with PDE5 inhibitors.
Related Concept Videos
01:28Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors
124
Phosphodiesterase 5 (PDE5) inhibitors are potent enzymes that function to hydrolyze cyclic nucleotides to their corresponding 5' monophosphates. Their unique biochemical properties have been applied in treating Pulmonary Arterial Hypertension (PAH).
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
124
01:26Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers
126
Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
126
01:23Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
142
Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
142
01:23Antihypertensive Drugs: Vasodilators
456
Vasodilators, primarily affecting the smooth muscles within arterial and venous walls, are commonly used for hypertension treatment. Medications such as minoxidil and hydralazine primarily target arteries and arterioles, while sodium nitroprusside acts on arterioles and venules. Minoxidil, functioning as a prodrug, is metabolized by hepatic sulfotransferase into its active form, minoxidil sulfate, after oral administration. This metabolite binds to the sulfonylurea receptor (SUR) component of...
456
01:25Antianginal Drugs: Calcium Channel Blockers and Ranolazine
437
Angina pectoris, a primary symptom of ischemic heart disease, requires careful pharmacological interventions. In this context, calcium channel blockers (CCBs) and ranolazine have emerged as crucial pharmacotherapeutic agents, providing deep insights into the complexities of angina management.
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...
437
01:28Nitric Oxide Signaling Pathway
4.9K
Nitric oxide (NO), an inorganic gas, acts as a potent second messenger in most animal and plant tissues. NO diffuses out of the cells that produce it and enters the neighboring cells to generate a downstream response. NO synthase (NOS) catalyzes NO production by the deamination of the amino acid arginine. There are three isoforms of NOS. Endothelial cells have endothelial NOS (eNOS), nerve and muscle cells have neuronal NOS (nNOS), and macrophages produce inducible NOS (iNOS) upon exposure...
4.9K